In Brief: Ephedrine letter
This article was originally published in The Tan Sheet
Executive Summary
Ephedrine letter: FDA sends April 17 warning letter to Bowling Green, Ky.-based Roman Pharmacraft for promoting its products containing ephedrine HCl as stimulants. FDA also cited the firm for marketing a phenylpropanolamine-containing diet aid that is not in a dosage form deferred from regulation by FDA...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning